Zurich Cantonal Bank’s Akebia Therapeutics AKBA Stock Holding History

Zurich Cantonal Bank’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,473	Closed	-$89.3K	–	2580
2025 Q4	$89.3K	Buy	+55,473	New	+$116K	﹤0.01%	2404

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Zurich Cantonal Bank's AKBA Position: Q4 2025 in Review

Zurich Cantonal Bank sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 55,473 shares — an estimated $116K sold.

Zurich Cantonal Bank first reported a position in AKBA in Q1 2018 and held it in 18 quarters. The position peaked at $210K in Q2 2020. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Zurich Cantonal Bank reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Zurich Cantonal Bank sold 55,473 Akebia Therapeutics shares in Q4 2025, an estimated $116K.
Zurich Cantonal Bank first reported a position in Akebia Therapeutics in Q1 2018 and held it in 18 quarters.
Zurich Cantonal Bank's Akebia Therapeutics position peaked at $210K in Q2 2020.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.